Zhong Jin Zai Xian·2025-07-11 09:16Core Insights - The launch of Kai Tong® Compound Alpha-Keto Acid Tablets on JD Health aims to improve accessibility for chronic kidney disease (CKD) patients, providing a more convenient and economical long-term treatment option [1][2] - Chronic kidney disease affects 132.3 million adults in China, with a prevalence rate of 10.8%, indicating a significant public health issue that requires effective prevention and management strategies [1][2] Group 1 - Kai Tong® Compound Alpha-Keto Acid Tablets are developed by Fresenius Kabi and comply with both EU and Chinese GMP quality standards, having been clinically validated in 61 countries over the past 40 years [2] - Clinical studies show that the use of Compound Alpha-Keto Acid Tablets, combined with a low-protein diet, can delay the progression of kidney disease and postpone the need for dialysis [2] - Fresenius Kabi has over 40 years of experience in the Chinese market, focusing on high-quality medical solutions for critically ill and chronic disease patients [2] Group 2 - JD Health collaborates with pharmaceutical partners, including Fresenius Kabi, to ensure quality drug supply for patients [2] - JD Health has established a comprehensive "medical + testing + diagnosis + medication" closed-loop system, providing a more convenient and professional one-stop treatment solution for chronic disease patients [2] - The company plans to deepen partnerships with pharmaceutical firms to enhance the accessibility of necessary medications for chronic diseases and improve the long-term medication experience for patients [2]